Why NQ Mobile, Vanda Pharmaceuticals, and Protective Life Are Today's 3 Best Stocks

Not even generally poor economic data can sink the broad-based S&P 500 (SNPINDEX: ^GSPC  ) , which reversed its fractional loss from yesterday to turn in yet another record-high close.

There was no bigger economic news today than the ADP National Employment Report, released before the opening bell, which showed that private businesses created just 179,000 jobs in May. That was below Wall Street's expectation that 210,000 private sector jobs would be created. The ADP numbers often give economists a better idea of what to expect for the subsequent Labor Department nonfarm payroll report, which is scheduled to be released on Friday. Based on today's data, we shouldn't expect the unemployment rate to dip any further from its present level of 6.3%.

Source: Bjorn Granberg, Flickr.

First-quarter worker productivity and unit labor cost figures from the Labor Deaprtment were also very concerning, especially for businesses. Worker productivity was revised from a prior dip of 1.7% to a decline of 3.2%, which was worse than expected. Inclement weather was the primary cause of this decline in activity, but a 5.7% increase in labor costs is far and away higher than anyone's wildest guess on Wall Street. Factory orders are moving higher again, so there's probably not an endemic problem here aside from the unpredictability of the weather, but it's still evident just how negatively the polar vortex affected the U.S. economy in the first quarter.

Even the Mortgage Bankers Association got in a jab on optimists today with its weekly loan originations reading dropping 3.1% from the previous week. Consumers continue to prove that they are hypersensitive to interest rate changes when they really shouldn't be considering that lending rates are near historic lows.

One bright spot came from the Institute for Supply Management services reading for May of 56.3, up from 55.2 in April. Similar to the first-quarter worker productivity numbers, a rebound here was expected as the weather around the country improved. If anything, this figure could provide a positive jolt for retailers that have taken it on the chin over the past couple months.

By day's end the S&P 500 had crawled out from the red and risen 3.64 points (0.19%) to close at 1,927.88, a fresh all-time high.

Leading all individual stocks to the upside today was mobile cloud security provider NQ Mobile (NYSE: NQ  ) , which skyrocketed 30.9% after announcing the findings from its special committee that was investigating allegations of fraud from short-selling firm Muddy Waters. According to the findings, which included verification of all cash balances, interviews with company employees, and investigations into its acquisitions and business partners, there is no evidence of wrongdoing. In addition, the special committee made recommendations that NQ Mobile can implement to tighten up its accounting controls. Per my Foolish colleague Steve Symington, Muddy Waters has already refuted the findings of the special committee and still believes NQ Mobile to be a fraud. I'd argue that as long as NQ follows the recommendations of the special committee and remains transparent to investors following this investigation, there is no reason it can't head even higher over the long term.

Coming in a close second behind NQ Mobile was Vanda Pharmaceuticals (NASDAQ: VNDA  ) , which gained 25.4% after the company announced that the European Medicines Agency (the EU's equivalent of our Food and Drug Administration) had accepted its application for marketing authorization for Hetlioz.


Source: StockMonkeys.com, Flickr.

Hetlioz is a non-24-hour sleep-wake disorder drug that was approved in the U.S. in January and helps blind people who have no light perception stay on a normal sleep schedule. Vanda estimates the EU could be home to roughly 130,000 people who could benefit from Hetlioz. Like any drug it'll need to be reviewed and approved in the EU before it can reach pharmacy shelves, but the potential to double its annual peak sales potential obviously has investors excited. However, I also watched Vanda mismanage its first FDA-approved therapy (Fanapt), which makes me want to stick to the sidelines and wait for Hetlioz's sales to do the talking rather than speculate on how good it could be.

Source: Kayugee, Flickr.

Lastly, life insurance and financial product and service provider Protective Life (NYSE: PL  ) , which has been the subject of buyout rumors all week, surged 18.1% after Dai-ichi Life Insurance officially agreed to purchase the company for $5.7 billion. According to Dai-ichi, its purchase of Protective Life will allow it to become a global insurer, especially considering that no country underwrites more life insurance policies than the United States. The deal is still subject to the approval of Protective Life shareholders, with a vote likely coming in the next two or three months. If approved, the buyout would be completed by the late fourth quarter or early 2015. It's hard to see Protective Life shareholders not approving this deal, with Dai-ichi paying eight times trailing EBITDA and 13 times forward earnings for Protective Life. All told, it looks like a solid long-term win for both companies.

These 3 stocks may have soared today, but none are likely going to be able to keep pace with this top stock over the long haul
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 04, 2014, at 8:38 PM, fossilmark wrote:

    While I agree that the EMA news today doesn't explain at 25% jump in Vanda's stock price, the rest of your comments about Vanda lack depth and probably miss the point. Fanapt was the 7th or 8th atypical antipsychotic, undifferentiated at best, and launching into a genericized market. Vanda did a FABULOUS job selling Fanapt to Novartis, pulling in $200M upfront, a 10% royalty, $250M in milestones, all while dumping execution responsibility and risk to Novartis, which pioneered the atypical class with Clozaril. Regarding the 25% stock jump today, you should look at the early prescription results announced today at the Jeffries conference.... At $84,000 per patient per year, the early numbers are very encouraging.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2982920, ~/Articles/ArticleHandler.aspx, 8/21/2014 12:21:58 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement